Parenteral meptazinol: a US clinical trial.
The effectiveness and safety of i.m. meptazinol (50, 100, 200mg), a unique mu 1-selective opioid analgesic, was compared with i.m. morphine (4, 8 and 16 mg) in 128 cancer patients with moderate to severe postoperative pain; 102 patients completed the crossover study. The study design was a modification of the sequential, twin-crossover assay. Meptazinol was found to be one-fifteenth to one-twentieth as potent as morphine on a mg basis, and to provide a more rapid time to peak effect (about 40 min vs 1 h) than morphine. Morphine improved selected aspects of mood while meptazinol did not. Sleepiness was the most common side effect on morphine (n = 43), and nausea was most common on meptazinol (n = 35). The incidence of side effects appeared to be dose-related for both drugs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001381:Azepines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008621:Meptazinol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009020:Morphine / Q000627:therapeutic use; D010149:Postoperative Pain / Q000517:prevention & control*; D013997:Time Factors
D001381:Azepines; D008621:Meptazinol; D009020:Morphine